
==== Front
Eur J Clin Nutr
Eur J Clin Nutr
European Journal of Clinical Nutrition
0954-3007
1476-5640
Nature Publishing Group UK London

34584224
991
10.1038/s41430-021-00991-6
Perspective
Role of the gut microbiome in chronic diseases: a narrative review
http://orcid.org/0000-0002-9595-5680
Vijay Amrita amrita.vijay@nottingham.ac.uk

1
http://orcid.org/0000-0003-1141-4471
Valdes Ana M. 12
1 grid.4563.4 0000 0004 1936 8868 Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, The University of Nottingham, Nottingham, UK
2 grid.240404.6 0000 0001 0440 1889 NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK
28 9 2021
28 9 2021
2022
76 4 489501
21 1 2021
29 6 2021
27 7 2021
© The Author(s) 2021, corrected publication 2022
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Subject terms

Biomarkers
Microbiology
NIHR Nottingham BRCissue-copyright-statement© Springer Nature Limited 2022
==== Body
pmcWhat is currently known on the topic

The gut microbiome, i.e., the community of bacteria and other microorganisms living in the human gut, has been implicated both directly and indirectly (mediating the effects of diet) on human health [1, 2]. The associations between gut microbiome composition and disease status have been widely reported, while recent studies have demonstrated a role for the gut microbiome in influencing remote organs, mucosal, and immune function [3, 4]. Considerable effort is currently focused on understanding the natural history of microbiome development in humans in the context of health outcomes, in parallel with improving our knowledge of microbiome–host molecular interactions. These efforts ultimately aim to develop effective approaches to rehabilitate perturbed human microbial ecosystems as a means to restore health and prevent disease. This review details the role of the gut microbiome in chronic diseases (Fig. 1) and ways it can be modulated for the management or prevention of chronic conditions.Fig. 1 Schematic representation of the association of the composition of the gut microbiome and gut-derived metabolites with chronic diseases.

The solid lines represent negative associations and the dashed lines represent positive associations of the disease phenotype with gut microbes and metabolites.

Differences in gut microbiome composition and function have been associated with a variety of chronic diseases ranging from gastrointestinal inflammatory and metabolic conditions to neurological, cardiovascular, and respiratory illnesses.

The aim of this narrative review is to describe the associations between gut microbiome composition and various types of chronic diseases and to discuss the links to habitual diet and dietary components (Table 1).Table 1 Summary of key findings outlining the role of the gut microbiome in chronic disease.

Key messages	
Gut microbiome composition is significantly different in healthy individuals compared to affected individuals with a broad range of chronic diseases. Lower microbiome diversity appears to be a common theme across many of the diseases	
Auto-immune diseases, in common with cardiometabolic diseases and irritable bowel syndrome, show low abundances of SCFA producing bacteria such as Bifidobacterium sp, Faecalibacterium sp, Roseburia sp, or Coprococcus eutactus	
High abundances of pathogenic bacteria (such as E. coli, S. aureus, and C. difficile) are common in some of these diseases	
SCFAs but also other microbial metabolites are involved in the health effects of gut microbiome composition and microbial metabolites can be better predictors of health outcomes than microbiome diversity	
Gut microbiome composition is modifiable by various therapeutic strategies. Dietary interventions can result in robust changes in both gut microbiome composition and function and in the corresponding health effects	

Gut microbiome and autoimmune disease

The pathogenesis of autoimmune diseases (AIDs) is not only attributed to genetic susceptibilities but also environmental factors, among which, a disturbed gut microbiota has attracted increasing attention. Compositional and functional changes of gut microbiota have been reported in various autoimmune diseases, and increasing evidence suggests that disturbed gut microbiota contributes to their immunopathogenesis.

Rheumatoid arthritis (RA)

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory condition that manifests in joint damage. It was recently demonstrated that different environmental factors are involved in the development of both intestinal/oral dysbiosis and arthritis onset and outcome, among which the most relevant are diet, smoking, and infections [5, 6]. The observation that germ-free mice are protected from development of experimental arthritis [7] suggests a possible role for the microbiome in the pathogenesis of this disease. The composition of the gut microbiota in RA patients free of therapy is severely altered compared to healthy controls. Chen et al. reported that compared with healthy controls, patients with RA show decreased gut microbial diversity, which correlates with autoantibody levels and disease duration [8]. In addition, at the compositional level, patients with RA show an increased abundance of Prevotella species, including Prevotella copri [8, 9], and recent preclinical phase studies on RA patients in European countries were shown to harbor a high abundance of this species in the intestine, suggesting that dysbiosis precedes the development of arthritis [10]. In contrast, Faecalibacterium, which is generally recognized as a beneficial microbe, is decreased in RA patients. Furthermore, the relative abundance of Collinsella was found to be increased in RA patients [11]. Interestingly, inoculation of Collinsella into collagen-induced arthritis (CIA)-susceptible mice induces severe arthritis. In vitro experiments showed that Collinsella Aerofaciens increases gut permeability and induces IL-17A expression, a key cytokine involved in the pathogenesis of RA, suggesting that Collinsella is a candidate arthritogenic bacterium in the human intestine [11]. In summary, Prevotella copri [12] and Collinsella are the dominant gut microbiota in patients with early RA and may be involved in its pathogenesis.

Recent links have been made between dietary intake of short-chain fatty acids (SCFAs) and autoimmune arthritis in mice, wherein SCFAs play an important role in the suppression of inflammation in RA [13, 14]. Mice deficient for SCFA receptors showed exacerbated inflammation in modes of RA [14]. Butyrate, one of the most abundant SCFAs, acts as an endogenous histone deacetylase (HDAC) inhibitor and has been shown to decrease inflammation in animal models of RA and other inflammatory diseases [15]. A recent study has revealed a role for intestinal barrier function, and specifically for zonulin, a peptide that controls epithelial tight junction permeability, in regulating the onset of joint disease in mice with collagen-induced arthritis (CIA) and potentially also in patients with RA [16]. Increased levels of zonulin have been associated with leaky intestinal barrier, dysbiosis, and inflammation. Restoration of the intestinal barrier in the period before clinical arthritis, either by dietary supplementation with the SCFA butyrate or pharmacological agents such as a zonulin antagonist may help delay disease onset and reduce the severity of RA.

Type 1 diabetes (T1D)

In humans, intestinal microbiota alterations, including loss of bacterial diversity, preceded the onset of metabolic symptoms associated with T1D [17]. Previous studies have linked several facets of gut health with the onset of T1D in humans and animal models [18–20]. In animal models, antibiotic-induced dysbiosis, altered microbial lipid metabolism, and suppressed enteric Th17 and T-reg cell populations have led to increased incidence of T1DM-like disease in mice [21]. Various human-based studies have also reported altered intestinal microbiota in connection to T1D from several ethnic groups [1720, 22–24]. The common findings from these studies include increased numbers of Bacteroides species, and deficiency of bacteria that produce SCFAs [25, 26] in cases of T1D. Specifically, the butyrate producer Faecalibacterium prausnitzii has been found to be decreased in abundance in children with diabetes-related autoantibodies [26].

In addition, increased intestinal permeability [22] and decreased microbial diversity [17] before T1D diagnosis have been reported. A multicenter case–control study of 783 children, showed that the microbiomes of healthy children contained more genes that were related to the fermentation and the biosynthesis of SCFAs, but these were not consistently associated with the abundance of particular taxa across geographically diverse clinical centers, suggesting that microbial function rather than composition was associated more with T1D [27].

The protective effects of SCFAs in T1D have been elucidated in animal studies that have looked at nonobese diabetic (NOD) mouse models [28]. For example, NOD mice fed specialized diets resulting in high bacterial release of acetate and butyrate were almost completely protected from T1D [28] mainly via the immune-modulating effects of SCFAs. In animal models of autoimmune diabetes, increased gut permeability precedes the development of diabetes, and environmental factors that modulate the permeability thereby modulate the incidence of the disease. Gut permeability appears to be an important factor in the relationship between the intestinal microbiota and the development of T1D. Both gut permeability and inflammation have been linked to the development of T1D in humans [26, 29].

Atopic eczema

Atopic eczema, a chronic inflammatory skin disorder, is most prevalent in early childhood. The pathogenesis of eczema has been attributed to skin-barrier dysfunctions, immune dysregulation as well as environmental–host–microbial interactions [30]. Environmental factors and modern lifestyle trends have been shown to indirectly contribute to pathogenesis of the disease through modulation of the gut microbiome [31].

Previous studies have found that the gut microbiome in early life is associated with age of onset, severity, and remission of atopic eczema [32, 33]. However, the association between gut microbiome diversity and atopic eczema development remains contradictory with few studies reporting an inverse relationship between gut diversity and the severity of atopic eczema [34, 35]. The development of atopic eczema may instead be driven by the interactions between specific gut microbiome signatures, the immune system, and the host. Specifically, in patients with atopic eczema, the proportion of Clostridia, Clostridium difficile, Escherichia coli, and Staphylococcus aureus in the gut microbiome is higher than in healthy controls, whereas that of Bifidobacteria, Bacteroidetes, and Bacteroides is decreased [34, 36–38]. The abundance of Clostridia and Escherichia coli in the intestine may be associated with atopic eczema via eosinophilic inflammation [36]. Butyrate-producing bacteria, such as Coprococcus eutactus, are increased in infants with milder atopic eczema or healthy infants than in those with severe atopic eczema [34]. Furthermore, fecal samples from patients with atopic eczema showed decreased levels of butyrate and propionate, which have anti-inflammatory effects. This is likely a consequence of a dysbiosis in the SCFA producer F prausnitzii that reduces the number of high butyrate and propionate strains [38].

It is evident that the compositional and proportional differences in the gut microbiome are associated with the development of AID via an immunomodulatory effect of the gut microbiome. The gut microbiome may contribute to the development, persistence, and severity of AID via immunologic, metabolic, and neuroendocrine pathways. It is however still unclear whether compositional changes in the gut microbiome precede the development of atopic eczema, and thereby shift the immune system and disrupt the gut epithelial barrier, making it amenable to the development of atopic eczema.

Atopic asthma

The rapid increase in asthma prevalence in industrialized nations over the past several decades cannot be explained by genetic risk factors alone and is thought to be related to altered environmental exposures associated with Western lifestyles. Early life is the most important period during which microbiota dysbiosis in the gut may lead to the development of many respiratory diseases, as the gut microbiota has a significant influence on immune-cell maturation and resistance to pathogens [39]. A number of validated epidemiological observations have implicated early-life environmental exposures in increased risk for childhood asthma. Many of these exposures are known to shape the nascent gut microbiome, including cesarean birth [40], antibiotic use [41], formula feeding, and other environmental factors including airborne toxins [42]. Further evidence for an intricate relationship between environmental exposure, the gut microbiome, and allergic airway disease comes from an expanding body of work, particularly those utilizing experimental animal models. For example, treating neonatal mice with antibiotics was shown to diminish gut microbial diversity, alter metabolite profiles, exacerbate immune cell response, and increase susceptibility to allergic lung inflammation [43, 44]. Furthermore, supplementation with SCFAs ameliorated airway inflammation in these mice, with the mechanism attributed to decreased activity of immune-modulating markers such as T cells, IL-4-producing CD4+ T cells, and reduced levels of circulating IgE [44].

Observational studies in humans have identified Proteobacteria to be the most dominant phylum overrepresented in patients with asthma compared with nonasthmatic volunteers across several studies [39]. The Proteobacteria phylum is represented by potentially pathogenic bacteria, including those that belong to the genera Haemophilus, Moraxella, and Neisseria [39].

Asthma pathogenesis and severity are linked with pro-inflammatory mechanisms. The effects of the gut microbiota on asthma are at least partially mediated by bacterial metabolites, which may influence immune responses in distal parts of the body. The most known metabolites with demonstrated protective properties in human airway inflammation are SCFAs. Children with high amounts of butyrate and propionate in feces at 1 year of age have significantly less atopic sensitization and are less likely to have asthma between 3 and 6 years [45]. In addition, soluble fiber may ameliorate the effects by exerting anti-inflammatory action via SCFAs binding to associated G-protein-coupled receptors (GPCRs) [46, 47].

Of recent interest are studies showing that gut bacteria in humans are able to produce other metabolites with pro- and anti-inflammatory potential, such as biogenic amines (including histamine) [48] and oxylipins such as 12,13-diHOME [49]. The number of histamine-secreting bacteria is significantly higher in fecal samples of asthma patients compared with nonasthmatic volunteers [50]. Furthermore, the number of histamine-secreting bacteria correlates with disease severity.

Although the mechanisms mediating communication between the gut and lungs are still unclear, it has been suggested that epithelial cells, other structural cells, and immune cells absorb signals from the gut endothelium to form a local cytokine microenvironment, which leads to changes in immune responses at distal sites [51]. Specifically, SCFAs derived from gut bacteria have inhibitory effects on proinflammatory responses in the lungs.

Gut microbiome–gut inflammation/bowel disorders

Irritable bowel syndrome (IBS)

IBS is generally characterized by abdominal pain, discomfort, and altered bowel habits. Although the etiology is multifactorial, recent understanding of the pathophysiology of IBS has revealed that variations in the normal gut microbiota may have a role to play in the low-grade intestinal inflammation associated with the syndrome [52]. Microbial dysbiosis in the gut is thought to be involved in IBS pathogenesis [53] and a recent study revealed a clear separation between the gut microbiota of patients with IBS and that of the controls. IBS was characterized by an increase in Firmicutes and, more specifically, in the numbers of Ruminococcus, Clostridium, and Dorea, in addition to a marked reduction of beneficial microbes such as Bifidobacterium and Faecalibacterium spp. [54]. Furthermore, systematic reviews have demonstrated the potentially harmful microbiota in patients with IBS, including phylum Proteobacteria, family Enterobacteriaceae (phylum Proteobacteria), family Lactobacillaceae, and genus Bacteroides (phylum Bacteroidetes). The Enterobacteriaceae family contains several pathogenic bacteria; for instance, Escherichia, Shigella, Campylobacter, and Salmonella [55]. These could either suggest previous intestinal infection in such patients or a change in the intestinal environment. By-products from these potentially harmful bacteria have been associated with some of the classical symptoms of IBS, including abdominal pain, bloating, and diarrhea [55].

The most consistent finding of a potentially “protective” bacterial group in IBS patients was found in the group of uncultured Clostridiales. Although the association is not causal and the mechanism of a protective effect in IBS symptoms is unclear. The genus Faecalibacterium, especially Faecalibacterium prausnitzii, which belongs to the similar order as the uncultured Clostridia, has been associated with maintaining gut mucosal health. This bacterium was considered as the main butyrate-producing and anti-inflammatory organism [56] and reduced IBS symptoms via mediation of IL-17 expression in a rat model [57, 58], as well as maintained gut-barrier integrity [59]. Furthermore, the genus Bifidobacterium was decreased significantly in IBS patients regardless of IBS subtype. Therefore, it was another promising potential genus in ameliorating IBS symptoms. A systematic review of probiotics in IBS has highlighted that Bifidobacterium-containing interventions reduce IBS symptoms, which are not seen in products that contain Lactobacillus alone [60].

Management of IBS symptoms can be achieved by the restriction of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP). Clinical studies have now shown the clinical efficacy of the low FODMAP diet in reducing IBS symptoms [61]. One consequence of this dietary intervention is its impact on gut microbiome composition as FODMAPs can modulate microbial composition and microbial metabolite production [62] and not all IBS subjects respond and there may be challenges with implementing a low FODMAP diet. Given the role of the microbiome in metabolizing poorly absorbed carbohydrates that depend on a person’s microbiome composition, that there has been increasing attention on the potential role of the gut microbiome in predicting low FODMAP diet efficacy [62] and recent data suggest that there are potential baseline differences in microbiome activity and composition, which can distinguish between low FODMAP diet responders and nonresponders [63].

Inflammatory bowel disease (IBD)

Long-lasting inflammation and ulceration of the colon are predominantly the main characteristics of IBD, which are features of Crohn’s disease (CD) and ulcerative colitis (UC). IBD, encompassing both ulcerative colitis and Crohn’s disease, is characterized by chronic and relapsing inflammation of the GI tract. The onset of both conditions is, in general, not thought to be due to a single causal organism but by a general microbial dysbiosis in the gut [64]. A role for gut microbes in the manifestation of IBD has been indicated by a number of studies and the gut microbiota are thought to be essential components in the development of mucosal lesions [65]. The alterations in the composition and functionality of the gut microbiota in IBD compared with non-IBD controls have been shown previously. In general, microbial dysbiosis in IBD is characterized by a decrease in diversity and stability of the microbiota [66–69]. Specifically, a decrease in Firmicutes and an increase in Proteobacteria taxa is the most consistent outcome from IBD microbiome studies. Furthermore, a common signature of microbial dysbiosis among IBD patients, especially in (active) CD, is the decreased abundance of Firmicutes bacteria belonging to the families Ruminococcaceae and Lachnospiraceae as opposed to healthy control samples [70–73]. Both families are important functional members of the human gut microbiota since most butyrate-producing bacteria from the human gut belong to them. Therefore, depletion of these bacterial families in IBD can be linked to the observed disturbance on a functional level, including a lower butyrate-producing capacity of the IBD microbiota [74]. In addition, a metagenomic and proteomics study in ileal CD microbiota demonstrated an underrepresentation of genes for SCFA production and a decrease in metagenomic reads and proteins of important butyrate producers Faecalibacterium prausnitzii and Roseburia sp. [75].

Butyrate has therapeutic potential in IBD because it serves as the main energy source for colonocytes, enhances epithelial barrier integrity, and inhibits inflammation. Recent observational and interventional studies have explored an alternative approach of probiotics, which involves the consumption of butyrate-producing bacteria to increase in situ butyrate production [76–78]. This may suggest that targeting microbial dysbiosis by supplementing butyrate-producing bacteria could restore gut homeostasis and health in IBD.

Gut microbiome composition and cardiometabolic diseases

Cardiovascular disease

The alterations in gut microbiota composition and the metabolic potential of gut microbiota have been identified as a contributing factor in Cardiovascular Disease (CVD) development [79]. Recently, mechanistic links between the gut microbiota and the severity of myocardial infarction have been reported in rats [80, 81]. Hypertension is the most prevalent modifiable risk factor for CVD. However, results from human studies remain scarce and conflicting. In the TwinsUK cohort [82], self‐reported hypertension was not related to 68 various microbiota markers. Furthermore, in the CARDIA study of 529 individuals an increase in alpha diversity resulted in a modest decrease in objectively measured systolic blood pressure (BP) [83]. More recently, the association between the gut microbiome and hypertension was studied on the well-phenotyped population of 6953 individuals as part of the FINRISK study [84] using standardized BP measurements. Although the associations between overall gut taxonomic composition and BP were weak, individuals with hypertension demonstrated changes in several microbiota genera, with most of these genera belonging to the Firmicutes phylum. Interestingly, most of the negative associations with BP belonged to the Lactobacillus species, specifically the greater abundance of Lactobacillus paracasei, a known probiotic that was associated with lower mean arterial pressure and lower dietary sodium intake which has also been reported previously by Wilck et al. [85].

Metabolism of certain dietary components such as choline and carnitine, which comprise a large component of a Western diet, has been shown to increase risk of cardiovascular disease mainly via the metabolism of these compounds to produce trimethylamine oxide (TMAO) [86, 87]. Gut-derived metabolites such as SCFAs have been recently shown to modulate blood pressure [88]. The suggested mechanism of SCFAs to modulate blood pressure is via the host G-protein coupled receptor (GPR) pathways that impact renin secretion and blood pressure regulation [88]. A series of studies using GPR41 knockout mice further supports involvement of these receptors in blood pressure control. This suggests that the gut microbiota are potentially intertwined functionally to control blood pressure, and their dysfunctions could be associated with hypertension. A recent study found that a Mediterranean diet which typically encompasses a high fiber diet followed by fasting was shown to reduce systolic blood pressure, need for antihypertensive medications, body-mass index at three months post intervention compared to following a Mediterranean diet alone [89]. These data highlight fasting followed by a shift to a health-promoting diet as a promising non-pharmacological intervention for patients with hypertension and other cardiometabolic diseases.

In rodent model studies, the administration of probiotics such as Lactobacillus plantarum and Lactobacillus rhamnosus was associated with improved ventricular function and attenuated heart failure after myocardial infarction [80, 90]. Furthermore, a meta-analysis demonstrated a significant decrease in blood pressure in patients treated with probiotics [91]. Lastly, supplementation of atherosclerosis-prone mice with A. muciniphila, a mucus colonizer protected against atherosclerosis development induced by feeding a Western diet [92]. These observations may suggest that probiotics use, in combination with standard medication, could offer additional benefits in the prevention and management of cardiovascular events.

Type 2 diabetes

Adults with T2DM have an altered gut microbiota composition compared to healthy controls. However, it is unclear whether these changes represent a cause or an effect and required further investigation. Among the commonly reported findings, the genera of Bifidobacterium, Bacteroides, Faecalibacterium, Akkermansia, and Roseburia were negatively associated with T2D, while the genera of Ruminococcus, Fusobacterium, and Blautia were positively associated with T2D [93, 94]. A large metagenome-wide association study found a moderate degree of gut dysbiosis in patients with T2DM [95]. Of the identifiable bacterial species, the control samples were enriched in various butyrate-producing bacteria and increased abundance of Lactobacillus spp., while patients with T2DM were characterized by an increase in certain opportunistic pathogens, such as a number of Clostridium spp. [95]. Overall, T2DM was associated with a reduced abundance of butyrate-producing bacteria and SCFAs, in particular butyrate which has been linked with insulin sensitivity [9, 96, 97]. The link between SCFAs and insulin sensitivity lies in the ability of SCFAs to trigger the secretion of GLP-1 by intestinal L-cells via specific G protein receptors (GPR41, GPR43) which has a substantial impact on pancreatic function and insulin release, as well as central effects regulating appetite [98, 99].

In addition to SCFAs, many other metabolites have been implicated in the role of gut microbiome composition and risk to T2DM. We have in fact reported reproducible associations between serum metabolites of microbial origin and gut microbiome alpha diversity in 1018 individuals from the Twins UK cohort [100]. The circulating levels of these metabolites were combined into a microbiome-metabolite score using a linear combination. Importantly the association of the microbiome metabolite score with cardiometabolic traits was stronger than the association between gut microbiome diversity and the same clinical traits. Specifically, the microbiome metabolite score was associated with prevalence and incidence of T2DM in the discovery cohort and this result was replicated in a multi-ethnic independent US cohort (n = 1522) showing the relevance of microbiome-derived metabolites in predicting risk and supporting their role as the mechanistic link between microbiome composition and health [100].

Non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) and the more advanced stage non-alcoholic steatohepatitis (NASH) are common comorbidities of obesity and T2DM with an increasing burden for society [101]. There is an increasing body of evidence linking the gut-liver axis to the development of NAFLD. Gut dysbiosis is directly related with increased intestinal permeability as a consequence of epithelial barrier deterioration, tight junctions’ alteration and bacterial translocation causing endotoxemia, which might reach and damage the liver through the portal vein [102–104]. Several studies have revealed alterations in the gut microbiome in people with NAFLD compared with healthy controls. We and others have reported a decrease in both alpha and beta diversities in NAFLD and its more advanced stages compared to healthy controls [105, 106]. Case control studies have reported consistent altered microbial signatures at phylum level such as increased Proteobacteria [107–110], at family level such as increased Enterobacteriaceae and genera such as an increase in the abundance of Collinsella sp, Escherichia, Dorea and a decrease in the abundance of Coprococcus, Eubacterium, Faecalibacterium and Prevotella [107, 111]. Similar microbial signatures were found in NASH as outlined in this recent review [112]. Although these initial results suggest a measurable contrast in microbial signatures between individuals with hepatic steatosis and controls, there are, however, large discrepancies found across studies with varying results in the literature. However, a common microbial signature that has been associated with other metabolic diseases is the reduction of levels of the butyrate producer F. prausnitzii in the more advanced forms of NAFLD [106, 113].

Several hypotheses have provided mechanistic insights into the pathways of how the gut microbiota might contribute to NAFLD development and its disease progression. Specific microbial species such as Collinsella sp. have been shown to metabolize bile acids to oxo-bile acid intermediates which may increase intestinal permeability and contribute to the development of NAFLD [114, 115]. Increased intestinal permeability may lead to lipopolysaccharide (LPS) release to the host, which can trigger tissue and systemic inflammation. Furthermore, the action of microbially-produced metabolites (including TMAO, choline or ethanol) and bile acid signaling can also affect host immunity [108, 116, 117]. Interestingly, unlike other diseases, SCFAs appear to prevent but also promote the development of NAFLD and NASH depending on the signaling pathway or mechanism they activate. Amongst the SCFAs, acetate was found to be enriched in fecal samples from adults with more advanced stages of NAFLD (i.e. fibrosis) [110], whereas butyrate and propionate were enriched in fecal samples from adults with mild or moderate NAFLD. This may suggest that levels and subtypes of SCFAs correlate with the severity of fatty liver disease. Since each SCFA exerts specific and somehow different metabolic effects, assessing their balance both at the fecal and systemic level in patients and after a dietary intervention using different substrates may help provide more information on their overall role in NAFLD development, exacerbation or improvement.

On the basis of the above, advances in discovering gut microbiota or microbiota-related metabolite signatures could be used as noninvasive diagnostic tools in NAFLD and its etiology.

Chronic kidney disease (CKD)

There has been a growing interest in studying the composition of the gut microbiota in patients with CKD as well as the mechanisms by which gut dysbiosis contributes to CKD progression. The influence of the gut microbiota on the gut–kidney axis acts in a reciprocal way with either CKD significantly modifying the composition and functions of the gut microbiota. Alternatively, the gut microbiota is able to manipulate the processes leading to CKD onset and progression through inflammatory, endocrine, and neurologic pathways. Therefore, understanding the complex interaction between these two organs may provide novel interventions to prevent the progression of CKD by targeting the gut microbiota.

The existence of intestinal microbiota alterations such as decrease of microbial richness, diversity, and uniformity has been related to CKD [118]. Patients with CDK show a lower colonization of Bifidobacterium sp, Lactobacillaceae, Bacteroidaceae, Akkermansia, and Prevotellaceae genera, and higher intestinal levels of Enterobacteriaceae, particularly Enterobacter, Klebsiella, and Escherichia, and also increased levels of Enterococci and Clostridium perfringes [119, 120]. The decrease in the abundance of Akkermansia muciniphilla, an important probiotic, in patients with CKD negatively correlated with plasma IL-10 levels, suggesting that an altered microbiota in CKD may promote chronic systemic inflammation [121]. This chronic systemic inflammation state represents a major risk factor for CKD progression.

CDK patients are characterized by decreased consumption of dietary fibers that are required for SCFA production. Lack of dietary fibers leads to increased amino nitrogen, which can be transformed into uremic toxins by the gut microbiota [122]. Patients with CDK are characterized by an imbalance between fermentative and proteolytic microbiota in favor of the latter. The imbalance in favor of proteolytic species is related to detrimental effects and also has a fundamental role in the progression of CKD [123]. Moreover, the main SCFAs especially butyrate, were found to be reduced in the feces and serum of patients during CKD development [123]. Further research is however needed to determine whether increasing levels of circulating SCFAs would provide any direct clinical benefit in patients with CDK.

Several experimental and clinical studies have shown the beneficial effects of prebiotic, probiotic, and synbiotic supplementation on gut microbiota–renal axis [124]. These have emerged as a potential therapeutic intervention to restore the imbalance of the gut microbiota, reduce inflammation or oxidative stress markers and modulate gut-derived uremic toxins, such as P‐cresyl sulfate (PCS), indoxyl sulfate (IS), and trimethylamine N‐oxide (TMAO), which have been implicated in the progression of CKD [125–127].

Mental health disorders

Gut microbes have been shown to also influence neurological functions and these links have been termed the “gut−brain axis” [128]. The gut microbiota communicates with the brain through three major pathways—the neural pathway (vagus nerve, enteric nervous system), the immune pathway (cytokines), and the endocrine pathway (HPA axis, gut hormones). Impaired functioning of this connection can lead to manifestation of mental disorders. Common gut microbial species belonging to the phylum Firmicutes and Actinobacteria, and the genera Bacteroides and Bifidobacterium, may be contributing to mental health disorders [129]. Different mental disorders are characterized by the differential gut microbial community that is generally predominated by a bacterial genus or a family as summarized in Table 2. Notably, in some of the disorders, there is an over-abundance of specific microbial species. For example, abundance of Lactobacillus sp. and Bifidobacterium sp. in disorders like schizophrenia (SCZ) [130] and attention-deficit hyperactivity disorder (ADHD) [131], respectively. The probable reason for this can be attributed to the complexity of the gut microbiota.Table 2 Studies (or reviews) on non-dietary interventions targeting the gut microbiome.

Therapy	Indication	Type of study/Reference	
FMT	T2D/metabolic syndrome	Interventional studies [163, 151]	
FMT	or C difficile infection –	Systematic review of RCTs [164]	
FMT	for ulcerative colitis –	Systematic review of RCTs [165]	
FMT	T1D –	RCT in [166]	
TMAO synthesis inhibitors	Lowering cholesterol and bile acid metabolism	Preclinical [167]	
TMAO synthesis inhibitors	Chronic kidney disease	Preclinical [168]	
TMAO synthesis inhibitors	Heart disease	Preclinical [169]	

Gut microbiota modulates the gut−brain axis via numerous direct and indirect ways. This includes maintaining gut permeability by modulating the integrity of tight junctions in the gut epithelium, producing a wide variety of metabolites including neurotransmitters, SCFAs, and amino acids. These gut-derived metabolites can affect the central nervous system by acting locally on the enteric nervous system or enter circulation and affect the brain. Furthermore, alteration in the levels of gut microbial metabolites, such as SCFAs, ammonia, tryptophan, and histamine have shown to be associated, directly or by breaking down into neuroactive catabolites with various neurological conditions like Parkinson’s disease (PD) [132], anorexia nervosa (AN) [133], Alzheimer’s disease (AD) [134], autism spectrum disorder (ASD) [135], and chronic stress and depression [136]. However, whether this disruption of homeostasis in the mental health disorders is the cause or effect of the alterations in gut microbiota and its functions is not emphatically clear and requires more studies.

Further, considering the evidence, several studies have been undertaken to specifically target the gut microbiota through different therapeutic interventions including administration of pre- and probiotics (psychobiotics) to treat mental health disorders and/or their symptoms [137, 138]. Human-intervention studies with psychotics such as the probiotic combinations of lactobacilli and Bifidobacteria showed significant reduction in psychological distress [139], improved cognition and communication among patients with AD [140] and ASD [141], and improving symptoms among PD patients [142]. Based on the promising effects of psychobiotics on modulating the gut−brain axis, more clinical trials are currently being conducted to identify the bacterial strains as potential candidates for treatment of mental disorders.

The gut microbiome as a therapeutic target in chronic diseases

Given the tight interplay between enteric microbial symbionts and host immunity (Fig. 1), efforts have focused on implementing various strategies targeting the gut microbiota to manage or prevent chronic diseases. Clinical approaches to modify gut microbiota generally focus on depleting overabundant members or the overall microbial load using antibiotics or antifungal agents, modulation through diet, or supplementation with live microbes (single or mixed species). There are a variety of proposed therapeutic approaches, such as dietary modifications, prebiotics, probiotics, and TMAO-synthesis inhibitors, to target the gut microbiome. More recently, fecal microbial transplantation (FMT) has been used in a range of infectious, neurological, and GI conditions, with promising outcomes (Table 3).Table 3 Summary table of key findings.

Disease group	Specific disease	Gut microbes	Main findings	
Autoimmune diseases	Rheumatoid arthritis	Prevotella copri.,	Increased in abundance [12, 13]	
		Collinsella sp.,	Increased in abundance [13]	
		Faecalibacterium sp.	Decreased in abundance, links to SCFA production [25]	
	Type-1 diabetes	Dialister invisus., Gemella sanguinis., Bifidobacterium longum	Increased in abundance (children), gut permeability [25]	
		F. prausnitzii	Decreased in abundance (children), butyrate (SCFA) production [28]	
	Atopic eczema	Clostridium difficile	Increased in abundance [37]	
		Escherichia coli	Increased in abundance, eosinophilic inflammation [37]	
		Staphylococcus aureus	Increased in abundance [37]	
		Bifidobacteria spp.	Decreased in abundance [37]	
		Bacteroidetes spp.	Decreased in abundance [38, 39]	
		Coprococcus eutactus	Decreased (in children), linked to butyrate production [39]	
		F. prausnitizii	Increased in abundance, SCFA production [41]	
	Atopic asthma	Various—Clostridium, Pediococcus, Escherichia, Klebsiella, Morganella, and Proteus spp.	Increased in abundance, increased bioamine (histamine) production [55]	
		Enterococcus faecalis, Streptococcus spp., Bifidobacterium bifidum., Lactobacillus spp.	Increased in abundance, increased bioamine (histamine) levels, increased epoxide hydrolase production of oxylipins (12,13-diHOME) [55, 56]	
Gut inflammation disorders	Irritable bowel syndrome	Ruminococcus spp., Clostridium spp., Dorea spp.	Increased in abundance [62]	
		Bifidobacterium spp.	Decreased significantly in abundance (all IBS subtypes) [62, 68]	
		Faecalibacterium spp.	Decreased in abundance, anti-inflammatory, butyrate production [62, 64, 65]	
		Enterobacteriaceae spp.	Increased, links to previous intestinal infection and pathogen byproducts [63]	
		Lactobacillaceae spp., Bacteroides spp.	Increased in abundance [63]	
	Inflammatory bowel disease	Ruminococcaceae spp., Lachnospiraceae spp.	Decreased in microbiome, butyrate production [78–81]	
		Faecalibacterium prausnitzii, Roseburia sp.	Decreased in microbiome, butyrate production [83]	
Cardiometabolic diseases	Cardiovascular disease (including hypertension)	Lactobacillus plantarum, Lactobacillus rhamnosus	Improved ventricular function and attenuated heart failure after myocardial infarction [90, 107]. Improved blood pressure [110]	
		Akkermansia muciniphila	Protected against atherosclerosis in mice [111]	
	Type-2 diabetes	Bifidobacterium, Bacteroides, Faecalibacterium Akkermansia and Roseburia spp.	Negative association [112, 113]	
		Ruminococcus, Fusobacterium, and Blautia	Positive association [112, 113]	
		Lactobacillus spp.	Enriched in control microbiome, butyrate production [112, 114, 115], insulin sensitivity through GLP-1 [116–120]	
		Clostridium spp.	Increased, opportunistic pathogen	
NAFLD		Collinsell spp.	Increased in abundance [128]. Increased intestinal permeability and lipopolysaccharide release through metabolism of bile-acids to oxo-bile [144, 145]	
		Escherichia spp., Dorea spp.	Increased in abundance [131, 135, 136]	
		Coprococcus spp., Eubacterium spp., Faecalibacterium spp.,

Prevotella spp.

	Decreased in abundance [131, 135, 137]	
Chronic kidney disease		Bifidobacterium, Lactobacillaceae, Prevotellaceae	Decreased in abundance, SCFA producers associated with anti-inflammatory cytokines [148, 149]	
		Enterobacter	Increased in abundance [149]	
		Klebsiella	Increased in abundance, pathogen associated with inflammatory disease states including Crohn’s [148, 149]	
		Clostridium perfringes	Increased in abundance, pathogen associated with intestinal diseases [148]	
Mental health disorders	SCZ, ADHD	Lactobacillus spp, Bifidobacterium	Increased in abundance in specific disorders such as SCZ and ADHD [157, 158]	
	General anxiety disorder (GAD)	Bacteriodetes, Ruminococcus gnavus, and Fusobacterium

Bacteroidaceae, Enterobacteriaceae, and Burkholderiaceae

	Decreased in abundance in general anxiety disorder (GAD) [170]. Increased in abundance in GAD [171, 172]	
	Post- traumatic stress disorder (PTSD)	Actinobacteria, Lentisphaerae, and Verrucomicrobia	Decreased in abundance in post-traumatic stress disorder (PTSD) [173]	
	Depression	Eggerthella., Holdemania, Turicibacter, Paraprevotella

Prevotella, Dialister

	Increased in abundance amongst individuals with depression [174, 175].

Decreased in abundance amongst individuals with depression [176]

	
	Dementia	Escherichia, Blautia, Bifidobacterium, Streptococcus, Lactobacillus, Dorea spp Actinobacteria, Bacteroides	Increased in abundance amongst individuals with dementia [177]. Decreased in abundance amongst individuals with dementia [177]	

More recently, the composition of the gut microbiome has been implicated in predicting the severity of COVID-19 possibly via its immune-modulatory properties. More specifically, gut commensals with known immunomodulatory potential, such as Faecalibacterium prausnitzii, Eubacterium rectale, and Bifidobacterium adolescentis, were found to be significantly under-represented in patients with COVID-19 compared with healthy controls and were also associated with disease severity after taking account of antibiotic use and patient age [143]. Furthermore, the microbial imbalance found in the COVID patients was also associated with raised levels of inflammatory cytokines and blood markers of tissue damage, such as C-reactive protein and certain enzymes. Based on these findings, increasing the levels of beneficial gut species depleted in COVID-19 could serve as a novel avenue to mitigate severe disease, highlighting the importance of the gut microbiota in the pathophysiology of COVID-19.

Despite encouraging evidence from animal models in which inflammatory conditions were successfully treated via gut microbiota manipulation, data from human trials is less conclusive. Findings from recent work showed that the ability of an introduced microbe to successfully colonize the gut depends on the structure of the resident gut microbiota [144], a factor that has so far been overlooked in microbial intervention-based clinical trials and that might explain discrepancies in animal models and human trials. Nonetheless, intervention with a multispecies consortium of bacteria has shown to be effective in the maintenance of remission in patients with UC but not in those with CD [145]. Meta-analysis of intervention trials in which various combinations of bacterial strains were administered to adults with T2DM showed moderate improvements in hyperglycemia [146]. Moreover, probiotic supplementation during the first 27 days of life reduced the risk of islet autoimmunity in a large multicenter prospective cohort study of children at high genetic risk for T1DM, compared with no supplementation or supplementation later in infancy [147].

Intervention studies involving live microbial supplementation have also shown encouraging results, although more attention to microbial strain selection based on functional attributes, defined timing or duration of supplementation, and/or tailoring of the supplemented organisms to the endogenous gut microbiome of the recipient may significantly improve the efficacy in future studies. Ongoing studies are focused on understanding the basis of microbe-microbe interactions in order to identify discrete gut microbiomes that more readily respond to specific microbial interventions.

There is also a great need for tailored interventions that consider the microbial individuality of the recipient in order to prevent or manage chronic diseases. Such approaches are likely to result in a transition away from historically used probiotic strains, which are frequently poorly adapted to the enteric microenvironment, toward personalized multispecies microbial consortia sourced from healthy human enteric ecosystems. To further enhance the efficacy of microbial supplementation, nutritional support in the form of targeted dietary modifications, tailored to the specific substrate requirements [148], should also be considered as discussed in the section below. Such an integrated approach to microbiome-based therapeutics, built on independent observations in the field of gut microbiome research, may offer more effective, predictable, and sustainable microbial restitution in cases of chronic disease in which microbiome perturbation and functional gene loss are prominent features.

FMT has proven effective in >90% of patients with recurrent antibiotic-resistant C. difficile infection [149]. The success rate of FMT administration for other chronic intestinal inflammatory conditions such as IBD, however, is more modest, with clinical remission being less predictable [150]. More recently, FMT has been applied to chronic inflammatory conditions affecting organs distal to the GI tract. FMT from lean donors improved insulin sensitivity in men with obesity and metabolic syndrome, and this improvement was linked to changes in plasma metabolites, in particular increased gamma-aminobutyric acid (GABA), tryptophan, and phenylalanine [151].

Effects of a healthy diet are mediated via the gut microbiome

The most obvious way of targeting the gut microbiome is through dietary modifications. Already, several controlled clinical dietary intervention studies targeting the human gut microbiota have been reported [2, 152]. For example, diets rich in fiber were shown to significantly improve glucose control and promote a healthier metabolic profile in T2DM patients as well as reduce the risk of coronary heart disease [153]. Other studies showed marked interindividual variation in postprandial glycemic responses after consumption of identical meals [154, 155]. The consideration of microbial composition alongside known disease-risk factors (i.e., body mass index, fasting glucose) enabled accurate glucose-response prediction, thus allowing the design of more effective, personalized diets for improved glycemic control [155] in these studies.

Some of these same studies have recently investigated the links between gut microbiome structure, habitual diet, and blood cardiometabolic markers [156] in a cohort of 1100 healthy individuals from the United States and the United Kingdom. This study reported that microbial diversity and composition were highly correlated with both fasting and postprandial biomarkers. The strongest associations were with high-density lipoprotein cholesterol (HDLC), which positively correlated with microbial species richness. Cardiometabolic markers, which have in the recent past been shown to be strongly predictive of incident diabetes and heart disease, such as glycoprotein acetyl (GlycA) were also associated (positively or negatively) with microbiome richness. One of the most striking findings of the study was that gut microbiome composition is a better predictor of postprandial triglyceride and insulin concentrations than of glucose levels. The authors also reported that the diversity of healthy plant-based foods in habitual diet shapes gut microbiome composition. Approximately 10% of the variance in gut microbial composition could be explained by variation in healthy eating patterns [156].

Bacterial species were found to segregate into groups associated with more and less healthy plant- and animal- based foods. In addition, the authors reported a microbial signature of cardiometabolic health levels consistent across diet, obesity indicators, and cardiometabolic risks. The authors reported a consistent set of microbial species that strongly linked to all of the following: healthy eating patterns, indicators of obesity and cardiometabolic health, and fasting and postprandial circulating metabolites connected with cardiometabolic risk [156]. Other much smaller studies have also reported that dietary habits are strongly correlated with gut microbiome composition, disease status, and SCFA production [129].

Although a key weakness of the above study is its cross-sectional observational nature, consistent changes in gut microbiome composition and health outcomes have been recently reported by an international consortium investigating the effect of 12 months of Mediterranean diet on 612 elderly individuals from five countries [157]. Shankar Ghosh et al. [157] reported significant differences in the association patterns of bacterial taxa that increased (DietPositive) or decreased (DietNegative) in response to the Mediterranean diet intervention. The DietPositive bacteria had consistent negative associations (significantly lower than the DietNegative bacteria) with the pro-inflammatory circulating markers hsCRP and IL-17 levels as well as with functional measures associated with increased frailty. In contrast, DietPostive bacterial taxa showed positive correlations with measures of improved cognitive function, hand-grip strength, and two of the anti-inflammatory cytokines. DietPositive species included butyrogenic taxa such as F. prausnitzii, Eubacterium and Roseburia, whereas DietNegative bacteria included Ruminococcus torques, Collinsella aerofaciens, Coprococcus comes, Dorea formicigenerans, and Clostridium ramosum. Interestingly, there is no overlap between the “DietPositive” bacteria whose abundance increased after 12 months of a Med Diet reported by Shankar Ghosh et al. [157] and the taxa associated with “healthy diet indices” reported by Asnicar et al. On the other hand, the “DietPositive” and “DietNegative” taxa have substantial overlap with results from our own recent interventional study. We compared the changes in gut microbiome composition after 6 weeks of 500 mg of omega-3 fatty acids or 20 g of soluble fiber (inulin) in 70 middle-age and elderly individuals who had low fiber intake at baseline [158]. We found that, consistent with what is known of prebiotics such as inulin, that Bifidobacterium sp was remarkably increased and this correlated with butyrate production. On the other hand, omega-3 supplementation resulted in a significant decrease in Collinsella sp, both of which are in line with the findings from the multicenter Mediterranean diet intervention [157]. Importantly, many of the changes in bacterial abundances and SCFA concentrations were accompanied by decreases in inflammatory or atherogenic molecular mediators such as VLDL or IL4. Unlike the effects seen through a complex dietary intervention, such as the Mediterranean diet, we showed that it is possible to see significant effects both on microbiome composition and cardiometabolic health mediators.

Other recent studies have highlighted the role of the type of dietary fat on gut microbiome composition. In a randomized trial, 38 overweight and obese subjects were assigned to consume an excess of 1000 kcal/day of diets rich in saturated fat, unsaturated fat, or simple sugars for 3 weeks [159]. The relative abundances of individual taxa were altered in a diet-specific manner, wherein the overfeeding of saturated fat increased Proteobacteria, while unsaturated fat increased butyrate producers.

It is indeed possible to target the increase of specific taxa and the production of specific metabolites and the extent to which different carbohydrate sources (digestible by gut bacteria but not by humans) alter gut microbiome composition and function was recently tested by Deehan et al. [148] in a randomized controlled trial using a four-arm design. They gave increasing doses of three forms of resistant starch from maize, potato, or tapioca and a human-digestible corn starch (placebo) to 10 healthy volunteers per arm. They compared the effect of these carbohydrate substrates on gut microbiome composition in humans and found that chemically modified resistant starches with small structural differences induced highly specific effects on the gut microbiome that direct changes in the output of either propionate or butyrate. Dominant effects were remarkably consistent within treatment groups and dose-dependent with a plateau at a dose of 35 g/day. For example, maize-derived resistant starch resulted in increases in B. adolescentis, E. rectale, Oscillibacter, and Ruminococcus-related taxa and this correlated with increases in butyrate production. Tapioca-resistant starch on the other hand, which induced shifts in propionate proportions, as positively correlated with increases in P. distasonis an important succinate-producing bacterium. Succinate is then converted to propionate by other commensal bacteria in the gut. This very elegant design also clearly demonstrated the dose dependency between carbohydrate sources and the production of specific SCFAs. Similar strong and specific effects on gut microbiome composition have been shown by many interventional studies, both in healthy [160, 161] and diseased populations [162].

Where is this field moving toward?

Over the past decade, considerable evidence from both animal and human studies has accumulated showing a clear link between the gut microbiome in chronic diseases, including inflammatory autoimmune disorders, gut inflammation-related disorders, and cardiometabolic diseases (Fig. 1). It is increasingly clear that bacterial metabolites are at least in part, the key agents involved in the role of the gut microbiome on human health and among such metabolites, SCFAs appear to be the most important ones. Butyrate-producing bacteria are associated with lower risk of inflammatory autoimmune and cardiometabolic diseases, and also irritable bowel syndrome (Table 1). A number of therapeutic strategies to target the gut microbiome are possible, but nutritional changes appear to be the most obvious, noninvasive, and immediate way of altering the gut microbiome composition and function. Recent randomized controlled trials have shown that both composition and function respond in consistent ways to specific dietary interventions. Dietary fiber and unsaturated fat, separately or in a healthy diet such as the Mediterranean diet, result in higher relative abundances of butyrate-producing bacteria and these bacteria and the SCFAs produced in turn result in improved health outcomes. Different types of dietary fiber result in different bacterial changes and different SCFAs. The possibility of designing dietary interventions targeted specifically at increasing certain bacterial metabolites to improve cardiometabolic and inflammatory health outcomes appears well within reach within the next half decade.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

4/4/2022

The super title Challenges in Nutrition was added.
==== Refs
References

1. Clemente JC Ursell LK Parfrey LW Knight R The impact of the gut microbiota on human health: an integrative view Cell 2012 148 1258 70 10.1016/j.cell.2012.01.035 22424233
2. Valdes AM Walter J Segal E Spector TD Role of the gut microbiota in nutrition and health BMJ 2018 361 k2179 10.1136/bmj.k2179 29899036
3. Belkaid Y Hand TW Role of the microbiota in immunity and inflammation Cell 2014 157 121 41 10.1016/j.cell.2014.03.011 24679531
4. Zheng D Liwinski T Elinav E Interaction between microbiota and immunity in health and disease Cell Res 2020 30 492 506 10.1038/s41422-020-0332-7 32433595
5. Guerreiro CS Calado Â Sousa J Fonseca JE Diet microbiota, and gut permeability-the unknown triad in rheumatoid arthritis Front Med 2018 5 349 10.3389/fmed.2018.00349
6. de Oliveira GLV Leite AZ Higuchi BS Gonzaga MI Mariano VS Intestinal dysbiosis and probiotic applications in autoimmune diseases Immunology 2017 152 1 12 10.1111/imm.12765 28556916
7. Scher JU Sczesnak A Longman RS Segata N Ubeda C Bielski C Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis Elife 2013 2 e01202 10.7554/eLife.01202 24192039
8. Wells PM Adebayo AS Bowyer RCE Freidin MB Finckh A Strowig T Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study Lancet Rheumatol 2020 2 e418 e427 10.1016/S2665-9913(20)30064-3 33345197
9. Donohoe DR Wali A Brylawski BP Bultman SJ Microbial regulation of glucose metabolism and cell-cycle progression in mammalian colonocytes PLoS One 2012 7 e46589 10.1371/journal.pone.0046589 23029553
10. Alpizar-Rodriguez D Lesker TR Gronow A Gilbert B Raemy E Lamacchia C Prevotella copri in individuals at risk for rheumatoid arthritis Ann Rheum Dis 2019 78 590 3 10.1136/annrheumdis-2018-214514 30760471
11. Chen J Wright K Davis JM Jeraldo P Marietta EV Murray J An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis Genome Med 2016 8 43 10.1186/s13073-016-0299-7 27102666
12. Zhang X Zhang D Jia H Feng Q Wang D Liang D The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment Nat Med 2015 21 895 905 10.1038/nm.3914 26214836
13. Chen Z Andreev D Oeser K Krljanac B Hueber A Kleyer A Th2 and eosinophil responses suppress inflammatory arthritis Nat Commun 2016 7 11596 10.1038/ncomms11596 27273006
14. Maslowski KM Vieira AT Ng A Kranich J Sierro F Yu D Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43 Nature 2009 461 1282 6 10.1038/nature08530 19865172
15. Wang L de Zoeten EF Greene MI Hancock WW Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells Nat Rev Drug Disco 2009 8 969 81 10.1038/nrd3031
16. Tajik N Frech M Schulz O Schälter F Lucas S Azizov V Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis Nat Commun 2020 11 1995 10.1038/s41467-020-15831-7 32332732
17. Kostic AD Gevers D Siljander H Vatanen T Hyötyläinen T Hämäläinen A-M The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes Cell Host Microbe 2015 17 260 73 10.1016/j.chom.2015.01.001 25662751
18. Knip M Siljander H The role of the intestinal microbiota in type 1 diabetes mellitus Nat Rev Endocrinol 2016 12 154 67 10.1038/nrendo.2015.218 26729037
19. Paun A Yau C Danska JS The influence of the microbiome on type 1 diabetes J Immunol 2017 198 590 5 10.4049/jimmunol.1601519 28069754
20. Needell JC Zipris D The role of the intestinal microbiome in type 1 diabetes pathogenesis Curr Diab Rep. 2016 16 89 10.1007/s11892-016-0781-z 27523648
21. Livanos AE Greiner TU Vangay P Pathmasiri W Stewart D McRitchie S Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice Nat Microbiol 2016 1 16140 10.1038/nmicrobiol.2016.140 27782139
22. Maffeis C Martina A Corradi M Quarella S Nori N Torriani S Association between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetes Diabetes Metab Res Rev 2016 32 700 9 10.1002/dmrr.2790 26891226
23. Mejía-León ME Petrosino JF Ajami NJ Domínguez-Bello MG de la Barca AMC Fecal microbiota imbalance in Mexican children with type 1 diabetes Sci Rep. 2014 4 3814 10.1038/srep03814 24448554
24. Alkanani AK Hara N Gottlieb PA Ir D Robertson CE Wagner BD Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 2015 64 3510 20 10.2337/db14-1847 26068542
25. de Goffau MC Fuentes S van den Bogert B Honkanen H de Vos WM Welling GW Aberrant gut microbiota composition at the onset of type 1 diabetes in young children Diabetologia 2014 57 1569 77 10.1007/s00125-014-3274-0 24930037
26. de Goffau MC Luopajärvi K Knip M Ilonen J Ruohtula T Härkönen T Fecal microbiota composition differs between children with β-cell autoimmunity and those without Diabetes 2013 62 1238 44 10.2337/db12-0526 23274889
27. Vatanen T Franzosa EA Schwager R Tripathi S Arthur TD Vehik K The human gut microbiome in early-onset type 1 diabetes from the TEDDY study Nature 2018 562 589 94 10.1038/s41586-018-0620-2 30356183
28. Mariño E Richards JL McLeod KH Stanley D Yap YA Knight J Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes Nat Immunol 2017 18 552 62 10.1038/ni.3713 28346408
29. Vaarala O Atkinson MA Neu J The ‘perfect storm’ for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity Diabetes 2008 57 2555 62 10.2337/db08-0331 18820210
30. Leung DYM Guttman-Yassky E Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches J Allergy Clin Immunol 2014 134 769 79 10.1016/j.jaci.2014.08.008 25282559
31. Ta LDH Chan JCY Yap GC Purbojati RW Drautz-Moses DI Koh YM A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema Gut Microbes 2020 12 1 22 10.1080/19490976.2020.1801964 33023370
32. Pothmann A Illing T Wiegand C Hartmann AA Elsner P The microbiome and atopic dermatitis: a review Am J Clin Dermatol 2019 20 749 61 10.1007/s40257-019-00467-1 31444782
33. Lee SY Lee E Park YM Hong SJ Microbiome in the gut-skin axis in atopic dermatitis Allergy Asthma Immunol Res 2018 10 354 62 10.4168/aair.2018.10.4.354 29949831
34. Nylund L Nermes M Isolauri E Salminen S de Vos WM Satokari R Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria Allergy 2015 70 241 4 10.1111/all.12549 25413686
35. Abrahamsson TR Jakobsson HE Andersson AF Björkstén B Engstrand L Jenmalm MC Low diversity of the gut microbiota in infants with atopic eczema J Allergy Clin Immunol 2012 129 434 40 10.1016/j.jaci.2011.10.025 22153774
36. Lee E Lee S-Y Kang M-J Kim K Won S Kim B-J Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation Ann Allergy Asthma Immunol 2016 117 91 92.e1 10.1016/j.anai.2016.04.019 27179583
37. Kirjavainen PV Arvola T Salminen SJ Isolauri E Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? Gut 2002 51 51 55 10.1136/gut.51.1.51 12077091
38. Song H Yoo Y Hwang J Na Y-C Kim HS Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis J Allergy Clin Immunol 2016 137 852 60 10.1016/j.jaci.2015.08.021 26431583
39. Barcik W Boutin RCT Sokolowska M Finlay BB The role of lung and gut microbiota in the pathology of asthma Immunity 2020 52 241 55 10.1016/j.immuni.2020.01.007 32075727
40. Chu DM Ma J Prince AL Antony KM Seferovic MD Aagaard KM Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery Nat Med 2017 23 314 26 10.1038/nm.4272 28112736
41. Korpela K Salonen A Virta LJ Kekkonen RA Forslund K Bork P Intestinal microbiome is related to lifetime antibiotic use in finnish pre-school children Nat Commun 2016 7 10410 10.1038/ncomms10410 26811868
42. Levin AM Sitarik AR Havstad SL Fujimura KE Wegienka G Cassidy-Bushrow AE Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity Sci Rep. 2016 6 31775 10.1038/srep31775 27558272
43. Russell SL Gold MJ Hartmann M Willing BP Thorson L Wlodarska M Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma EMBO Rep. 2012 13 440 7 10.1038/embor.2012.32 22422004
44. Cait A Hughes MR Antignano F Cait J Dimitriu PA Maas KR Microbiome-driven allergic lung inflammation is ameliorated by short-chain fatty acids Mucosal Immunol 2018 11 785 95 10.1038/mi.2017.75 29067994
45. Roduit C Frei R Ferstl R Loeliger S Westermann P Rhyner C High levels of butyrate and propionate in early life are associated with protection against atopy Allergy 2019 74 799 809 10.1111/all.13660 30390309
46. Williams LM Scott HA Wood LG Soluble fibre as a treatment for inflammation in asthma J Nutr Intermed Metab 2019 18 100108 10.1016/j.jnim.2019.100108
47. McLoughlin R Berthon BS Rogers GB Baines KJ Leong LEX Gibson PG Soluble fibre supplementation with and without a probiotic in adults with asthma: A 7-day randomised, double blind, three way cross-over trial EBioMedicine 2019 46 473 85 10.1016/j.ebiom.2019.07.048 31375426
48. Pugin B Barcik W Westermann P Heider A Wawrzyniak M Hellings P A wide diversity of bacteria from the human gut produces and degrades biogenic amines Micro Ecol Health Dis 2017 28 1353881
49. Stewart CJ Homing in on 12,13-diHOME in asthma Nat Microbiol 2019 4 1774 5 10.1038/s41564-019-0599-y 31649356
50. Barcik W Pugin B Brescó MS Westermann P Rinaldi A Groeger D Bacterial secretion of histamine within the gut influences immune responses within the lung Allergy 2019 74 899 909 10.1111/all.13709 30589936
51. Budden KF Gellatly SL Wood DLA Cooper MA Morrison M Hugenholtz P Emerging pathogenic links between microbiota and the gut-lung axis Nat Rev Microbiol 2017 15 55 63 10.1038/nrmicro.2016.142 27694885
52. Brint EK MacSharry J Fanning A Shanahan F Quigley EMM Differential expression of toll-like receptors in patients with irritable bowel syndrome Am J Gastroenterol 2011 106 329 36 10.1038/ajg.2010.438 21102570
53. Ghoshal UC Shukla R Ghoshal U Gwee K-A Ng SC Quigley EMM The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012 2012 151085 22577594
54. Rajilić-Stojanović M Biagi E Heilig HGHJ Kajander K Kekkonen RA Tims S Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome Gastroenterology 2011 141 1792 801 10.1053/j.gastro.2011.07.043 21820992
55. Pittayanon R Lau JT Yuan Y Leontiadis GI Tse F Surette M Gut microbiota in patients with irritable bowel syndrome-a systematic review Gastroenterology 2019 157 97 108 10.1053/j.gastro.2019.03.049 30940523
56. Lopez-Siles M Duncan SH Garcia-Gil LJ Martinez-Medina M Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics ISME J 2017 11 841 52 10.1038/ismej.2016.176 28045459
57. Zhang M Qiu X Zhang H Yang X Hong N Yang Y Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats PLoS One 2014 9 e109146 10.1371/journal.pone.0109146 25275569
58. Wang H Gong J Wang W Long Y Fu X Fu Y Are there any different effects of bifidobacterium, lactobacillus and streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? PLoS One 2014 9 e90153 10.1371/journal.pone.0090153 24595218
59. Rivière A Selak M Lantin D Leroy F De Vuyst L Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut Front Microbiol 2016 7 979 10.3389/fmicb.2016.00979 27446020
60. Ford AC Harris LA Lacy BE Quigley EMM Moayyedi P Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome Aliment Pharm Ther 2018 48 1044 60 10.1111/apt.15001
61. Dionne J Ford AC Yuan Y Chey WD Lacy BE Saito YA A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low fodmaps diet in treating symptoms of irritable bowel syndrome Am J Gastroenterol 2018 113 1290 1300 10.1038/s41395-018-0195-4 30046155
62. Chumpitazi BP The gut microbiome as a predictor of low fermentable oligosaccharides disaccharides monosaccharides and polyols diet efficacy in functional bowel disorders Curr Opin Gastroenterol 2020 36 147 54 10.1097/MOG.0000000000000608 31850930
63. Leshem A, Segal E, Elinav E. The gut microbiome and individual-specific responses to diet. mSystems. 2020;5. 10.1128/mSystems.00665-20.
64. Lepage P Häsler R Spehlmann ME Rehman A Zvirbliene A Begun A Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis Gastroenterology 2011 141 227 36 10.1053/j.gastro.2011.04.011 21621540
65. Manichanh C Borruel N Casellas F Guarner F The gut microbiota in IBD Nat Rev Gastroenterol Hepatol 2012 9 599 608 10.1038/nrgastro.2012.152 22907164
66. Ott SJ Musfeldt M Wenderoth DF Hampe J Brant O Fölsch UR Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease Gut 2004 53 685 93 10.1136/gut.2003.025403 15082587
67. Walker AW Sanderson JD Churcher C Parkes GC Hudspith BN Rayment N High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease BMC Microbiol 2011 11 7 10.1186/1471-2180-11-7 21219646
68. Tong M Li X Wegener Parfrey L Roth B Ippoliti A Wei B A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease PLoS One 2013 8 e80702 10.1371/journal.pone.0080702 24260458
69. Martinez C Antolin M Santos J Torrejon A Casellas F Borruel N Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission Am J Gastroenterol 2008 103 643 8 10.1111/j.1572-0241.2007.01592.x 18341488
70. Matsuoka K Kanai T The gut microbiota and inflammatory bowel disease Semin Immunopathol 2015 37 47 55 10.1007/s00281-014-0454-4 25420450
71. Kostic AD Xavier RJ Gevers D The microbiome in inflammatory bowel disease: current status and the future ahead Gastroenterology 2014 146 1489 99 10.1053/j.gastro.2014.02.009 24560869
72. Halfvarson J Brislawn CJ Lamendella R Vázquez-Baeza Y Walters WA Bramer LM Dynamics of the human gut microbiome in inflammatory bowel disease Nat Microbiol 2017 2 17004 10.1038/nmicrobiol.2017.4 28191884
73. Mottawea W Chiang C-K Mühlbauer M Starr AE Butcher J Abujamel T Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn’s disease Nat Commun 2016 7 13419 10.1038/ncomms13419 27876802
74. Marchesi JR Holmes E Khan F Kochhar S Scanlan P Shanahan F Rapid and noninvasive metabonomic characterization of inflammatory bowel disease J Proteome Res 2007 6 546 51 10.1021/pr060470d 17269711
75. Morgan XC Tickle TL Sokol H Gevers D Devaney KL Ward DV Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment Genome Biol 2012 13 R79 10.1186/gb-2012-13-9-r79 23013615
76. Van Immerseel F Ducatelle R De Vos M Boon N Van De Wiele T Verbeke K Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease J Med Microbiol 2010 59 141 3 10.1099/jmm.0.017541-0 19942690
77. Miquel S Martín R Rossi O Bermúdez-Humarán LG Chatel JM Sokol H Faecalibacterium prausnitzii and human intestinal health Curr Opin Microbiol 2013 16 255 61 10.1016/j.mib.2013.06.003 23831042
78. Tamanai-Shacoori Z Smida I Bousarghin L Loreal O Meuric V Fong SB Roseburia spp.: a marker of health? Future Microbiol 2017 12 157 70 10.2217/fmb-2016-0130 28139139
79. Tang WHW Kitai T Hazen SL Gut microbiota in cardiovascular health and disease Circ Res 2017 120 1183 96 10.1161/CIRCRESAHA.117.309715 28360349
80. Lam V Su J Koprowski S Hsu A Tweddell JS Rafiee P Intestinal microbiota determine severity of myocardial infarction in rats FASEB J 2012 26 1727 35 10.1096/fj.11-197921 22247331
81. Lam V Su J Hsu A Gross GJ Salzman NH Baker JE Intestinal microbial metabolites are linked to severity of myocardial infarction in rats PLoS One 2016 11 e0160840 10.1371/journal.pone.0160840 27505423
82. Jackson MA Verdi S Maxan M-E Shin CM Zierer J Bowyer RCE Gut microbiota associations with common diseases and prescription medications in a population-based cohort Nat Commun 2018 9 2655 10.1038/s41467-018-05184-7 29985401
83. Sun S Lulla A Sioda M Winglee K Wu MC Jacobs DR Jr Gut microbiota composition and blood pressure Hypertension 2019 73 998 1006 10.1161/HYPERTENSIONAHA.118.12109 30905192
84. Palmu J Salosensaari A Havulinna AS Cheng S Inouye M Jain M Association between the gut microbiota and blood pressure in a population cohort of 6953 Individuals J Am Heart Assoc 2020 9 e016641 10.1161/JAHA.120.016641 32691653
85. Wilck N Matus MG Kearney SM Olesen SW Forslund K Bartolomaeus H Salt-responsive gut commensal modulates TH17 axis and disease Nature 2017 551 585 9 10.1038/nature24628 29143823
86. Wang Z Klipfell E Bennett BJ Koeth R Levison BS Dugar B Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease Nature 2011 472 57 63 10.1038/nature09922 21475195
87. Baker JL Havas KA Miller LA Lacy WA Schlanser J Gunshot wounds in military working dogs in operation enduring freedom and operation Iraqi freedom: 29 cases (2003-9) J Vet Emerg Crit Care 2013 23 47 52 10.1111/j.1476-4431.2012.00823.x
88. Pluznick JL Protzko RJ Gevorgyan H Peterlin Z Sipos A Han J Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation Proc Natl Acad Sci USA 2013 110 4410 5 10.1073/pnas.1215927110 23401498
89. Maifeld A Bartolomaeus H Löber U Avery EG Steckhan N Markó L Fasting alters the gut microbiome reducing blood pressure and body weight in metabolic syndrome patients Nat Commun 2021 12 1970 10.1038/s41467-021-22097-0 33785752
90. Gan XT Ettinger G Huang CX Burton JP Haist JV Rajapurohitam V Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat Circ Heart Fail 2014 7 491 9 10.1161/CIRCHEARTFAILURE.113.000978 24625365
91. Khalesi S Sun J Buys N Jayasinghe R Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials Hypertension 2014 64 897 903 10.1161/HYPERTENSIONAHA.114.03469 25047574
92. Li J Lin S Vanhoutte PM Woo CW Xu A Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in apoe-/- mice Circulation 2016 133 2434 46 10.1161/CIRCULATIONAHA.115.019645 27143680
93. Larsen N Vogensen FK van den Berg FWJ Nielsen DS Andreasen AS Pedersen BK Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults PLoS One 2010 5 e9085 10.1371/journal.pone.0009085 20140211
94. Gurung M Li Z You H Rodrigues R Jump DB Morgun A Role of gut microbiota in type 2 diabetes pathophysiology EBioMedicine 2020 51 102590 10.1016/j.ebiom.2019.11.051 31901868
95. Qin J Li Y Cai Z Li S Zhu J Zhang F A metagenome-wide association study of gut microbiota in type 2 diabetes Nature 2012 490 55 60 10.1038/nature11450 23023125
96. Vrieze A Out C Fuentes S Jonker L Reuling I Kootte RS Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity J Hepatol 2014 60 824 31 10.1016/j.jhep.2013.11.034 24316517
97. Donohoe DR Garge N Zhang X Sun W O’Connell TM Bunger MK The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon Cell Metab 2011 13 517 26 10.1016/j.cmet.2011.02.018 21531334
98. Tolhurst G Heffron H Lam YS Parker HE Habib AM Diakogiannaki E Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2 Diabetes 2012 61 364 71 10.2337/db11-1019 22190648
99. Fava S Glucagon-like peptide 1 and the cardiovascular system Curr Diabetes Rev 2014 10 302 10 10.2174/1573399810666141030125830 25360712
100. Menni C Zhu J Le Roy CI Mompeo O Young K Rebholz CM Serum metabolites reflecting gut microbiome alpha diversity predict type 2 diabetes Gut Microbes 2020 11 1632 42 10.1080/19490976.2020.1778261 32576065
101. Estes C Razavi H Loomba R Younossi Z Sanyal AJ Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease Hepatology 2018 67 123 33 10.1002/hep.29466 28802062
102. De Gottardi A McCoy KD Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease J Hepatol 2011 55 1181 3 10.1016/j.jhep.2011.05.003 21703167
103. Sabaté J-M Jouët P Harnois F Mechler C Msika S Grossin M High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis Obes Surg 2008 18 371 7 10.1007/s11695-007-9398-2 18286348
104. Moreira APB Texeira TFS Ferreira AB Peluzio M do CG Alfenas R de CG Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia Br J Nutr 2012 108 801 9 10.1017/S0007114512001213 22717075
105. Astbury S Atallah E Vijay A Aithal GP Grove JI Valdes AM Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis Gut Microbes 2020 11 569 80 10.1080/19490976.2019.1681861 31696774
106. Caussy C Tripathi A Humphrey G Bassirian S Singh S Faulkner C A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease Nat Commun 2019 10 1406 10.1038/s41467-019-09455-9 30926798
107. Hoyles L Fernández-Real J-M Federici M Serino M Abbott J Charpentier J Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women Nat Med 2018 24 1070 80 10.1038/s41591-018-0061-3 29942096
108. Shen F Zheng R-D Sun X-Q Ding W-J Wang X-Y Fan J-G Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease Hepatobiliary Pancreat Dis Int 2017 16 375 81 10.1016/S1499-3872(17)60019-5 28823367
109. Raman M Ahmed I Gillevet PM Probert CS Ratcliffe NM Smith S Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 2013 11 868 75 10.1016/j.cgh.2013.02.015 23454028
110. Loomba R Seguritan V Li W Long T Klitgord N Bhatt A Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease Cell Metab 2017 25 1054 10.1016/j.cmet.2017.04.001 28467925
111. Boursier J Mueller O Barret M Machado M Fizanne L Araujo-Perez F The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota Hepatology 2016 63 764 75 10.1002/hep.28356 26600078
112. Aron-Wisnewsky J Vigliotti C Witjes J Le P Holleboom AG Verheij J Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders Nat Rev Gastroenterol Hepatol 2020 17 279 97 10.1038/s41575-020-0269-9 32152478
113. Iebba V Guerrieri F Di Gregorio V Levrero M Gagliardi A Santangelo F Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy Sci Rep. 2018 8 8210 10.1038/s41598-018-26509-y 29844325
114. Doden H, Sallam LA, Devendran S, Ly L, Doden G, Daniel SL, et al. Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. Appl Environ Microbiol. 2018;84. 10.1128/AEM.00235-18.
115. Stenman LK Holma R Eggert A Korpela R A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids Am J Physiol Gastrointest Liver Physiol 2013 304 G227 34 10.1152/ajpgi.00267.2012 23203158
116. Aron-Wisnewsky J Gaborit B Dutour A Clement K Gut microbiota and non-alcoholic fatty liver disease: new insights Clin Microbiol Infect 2013 19 338 48 10.1111/1469-0691.12140 23452163
117. Brandl K Schnabl B Intestinal microbiota and nonalcoholic steatohepatitis Curr Opin Gastroenterol 2017 33 128 33 10.1097/MOG.0000000000000349 28257306
118. Onal EM Afsar B Covic A Vaziri ND Kanbay M Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease Hypertens Res 2019 42 123 40 10.1038/s41440-018-0144-z 30504819
119. Jazani NH, Savoj J, Lustgarten M, Lau WL, Vaziri ND. Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease. Diseases. 2019;7. 10.3390/diseases7010021.
120. Sircana A De Michieli F Parente R Framarin L Leone N Berrutti M Gut microbiota, hypertension and chronic kidney disease: recent advances Pharm Res 2019 144 390 408 10.1016/j.phrs.2018.01.013
121. Li F Wang M Wang J Li R Zhang Y Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease Front Cell Infect Microbiol 2019 9 206 10.3389/fcimb.2019.00206 31245306
122. Vaziri ND Wong J Pahl M Piceno YM Yuan J DeSantis TZ Chronic kidney disease alters intestinal microbial flora Kidney Int 2013 83 308 15 10.1038/ki.2012.345 22992469
123. Yang T Richards EM Pepine CJ Raizada MK The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease Nat Rev Nephrol 2018 14 442 56 10.1038/s41581-018-0018-2 29760448
124. Mafra D, Borges N, Alvarenga L, Esgalhado M, Cardozo L, Lindholm B, et al. Dietary components that may influence the disturbed gut microbiota in chronic kidney disease. Nutrients. 2019;11. 10.3390/nu11030496.
125. Tayebi-Khosroshahi H Habibzadeh A Niknafs B Ghotaslou R Yeganeh Sefidan F Ghojazadeh M The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial J Ren Inj Prev 2016 5 162 7 10.15171/jrip.2016.34 27689115
126. Wanchai K Yasom S Tunapong W Chunchai T Thiennimitr P Chaiyasut C Prebiotic prevents impaired kidney and renal Oat3 functions in obese rats J Endocrinol 2018 237 29 42 10.1530/JOE-17-0471 29483238
127. Van Hung T Suzuki T Dietary fermentable fibers attenuate chronic kidney disease in mice by protecting the intestinal barrier J Nutr 2018 148 552 61 10.1093/jn/nxy008 29659957
128. Mayer EA Tillisch K Gupta A Gut/brain axis and the microbiota J Clin Invest 2015 125 926 38 10.1172/JCI76304 25689247
129. Maldonado-Contreras A Noel SE Ward DV Velez M Mangano KM Associations between diet, the gut microbiome, and short-chain fatty acid production among older Caribbean Latino adults J Acad Nutr Diet 2020 120 2047 .e6 10.1016/j.jand.2020.04.018 32798072
130. Zhu F Ju Y Wang W Wang Q Guo R Ma Q Metagenome-wide association of gut microbiome features for schizophrenia Nat Commun 2020 11 1612 10.1038/s41467-020-15457-9 32235826
131. Prehn-Kristensen A Zimmermann A Tittmann L Lieb W Schreiber S Baving L Reduced microbiome alpha diversity in young patients with ADHD PLoS One 2018 13 e0200728 10.1371/journal.pone.0200728 30001426
132. Caspani G Kennedy S Foster JA Swann J Gut microbial metabolites in depression: understanding the biochemical mechanisms Micro Cell Fact 2019 6 454 81 10.15698/mic2019.10.693
133. Roubalová R Procházková P Papežová H Smitka K Bilej M Tlaskalová-Hogenová H Anorexia nervosa: gut microbiota-immune-brain interactions Clin Nutr 2020 39 676 84 10.1016/j.clnu.2019.03.023 30952533
134. Zhang L Wang Y Xiayu X Shi C Chen W Song N Altered gut microbiota in a mouse model of Alzheimer’s disease J Alzheimers Dis 2017 60 1241 57 10.3233/JAD-170020 29036812
135. Wang L Christophersen CT Sorich MJ Gerber JP Angley MT Conlon MA Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder Dig Dis Sci 2012 57 2096 102 10.1007/s10620-012-2167-7 22535281
136. Galland L The gut microbiome and the brain J Med Food 2014 17 1261 72 10.1089/jmf.2014.7000 25402818
137. Barbosa RSD Vieira-Coelho MA Probiotics and prebiotics: focus on psychiatric disorders – a systematic review Nutr Rev 2020 78 437 50 10.1093/nutrit/nuz080 31769847
138. Ansari F Pourjafar H Tabrizi A Homayouni A The effects of probiotics and prebiotics on mental disorders: a review on depression, anxiety, Alzheimer, and autism spectrum disorders Curr Pharm Biotechnol 2020 21 555 65 10.2174/1389201021666200107113812 31914909
139. Messaoudi M Lalonde R Violle N Javelot H Desor D Nejdi A Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects Br J Nutr 2011 105 755 64 10.1017/S0007114510004319 20974015
140. Akbari E Asemi Z Daneshvar Kakhaki R Bahmani F Kouchaki E Tamtaji OR Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial Front Aging Neurosci 2016 8 256 10.3389/fnagi.2016.00256 27891089
141. Nimgampalle M Kuna Y Anti-Alzheimer properties of probiotic, lactobacillus plantarum MTCC 1325 in Alzheimer’s disease induced albino rats J Clin Diagn Res 2017 11 KC01 KC05 28969160
142. Tamtaji OR Taghizadeh M Daneshvar Kakhaki R Kouchaki E Bahmani F Borzabadi S Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial Clin Nutr 2019 38 1031 5 10.1016/j.clnu.2018.05.018 29891223
143. Yeoh YK, Zuo T, Lui GC-Y, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021. 10.1136/gutjnl-2020-323020.
144. Zmora N Zilberman-Schapira G Suez J Mor U Dori-Bachash M Bashiardes S Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features Cell 2018 174 1388 .e21 10.1016/j.cell.2018.08.041 30193112
145. Abraham B Quigley EMM Antibiotics and probiotics in inflammatory bowel disease: when to use them? Frontline Gastroenterol 2020 11 62 9 10.1136/flgastro-2018-101057 31885842
146. Samah S Ramasamy K Lim SM Neoh CF Probiotics for the management of type 2 diabetes mellitus: a systematic review and meta-analysis Diabetes Res Clin Pr 2016 118 172 82 10.1016/j.diabres.2016.06.014
147. Uusitalo U Liu X Yang J Aronsson CA Hummel S Butterworth M Association of early exposure of probiotics and islet autoimmunity in the TEDDY Study JAMA Pediatr 2016 170 20 8 10.1001/jamapediatrics.2015.2757 26552054
148. Deehan EC Yang C Perez-Muñoz ME Nguyen NK Cheng CC Triador L Precision microbiome modulation with discrete dietary fiber structures directs short-chain fatty acid production Cell Host Microbe 2020 27 389 404.e6 10.1016/j.chom.2020.01.006 32004499
149. van Nood E Vrieze A Nieuwdorp M Fuentes S Zoetendal EG de Vos WM Duodenal infusion of donor feces for recurrent Clostridium difficile N. Engl J Med 2013 368 407 15 10.1056/NEJMoa1205037 23323867
150. Colman RJ Rubin DT Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis J Crohns Colitis 2014 8 1569 81 10.1016/j.crohns.2014.08.006 25223604
151. Kootte RS Levin E Salojärvi J Smits LP Hartstra AV Udayappan SD Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition Cell Metab 2017 26 611 .e6 10.1016/j.cmet.2017.09.008 28978426
152. Cotillard A Kennedy SP Kong LC Prifti E Pons N Le Chatelier E Dietary intervention impact on gut microbial gene richness Nature 2013 500 585 8 10.1038/nature12480 23985875
153. Pereira MA O’Reilly E Augustsson K Fraser GE Goldbourt U Heitmann BL Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies Arch Intern Med 2004 164 370 6 10.1001/archinte.164.4.370 14980987
154. Berry SE Valdes AM Drew DA Asnicar F Mazidi M Wolf J Human postprandial responses to food and potential for precision nutrition Nat Med 2020 26 964 73 10.1038/s41591-020-0934-0 32528151
155. Zeevi D Korem T Zmora N Israeli D Rothschild D Weinberger A Personalized nutrition by prediction of glycemic responses Cell 2015 163 1079 94 10.1016/j.cell.2015.11.001 26590418
156. Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021. 10.1038/s41591-020-01183-8.
157. Ghosh TS Rampelli S Jeffery IB Santoro A Neto M Capri M Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries Gut 2020 69 1218 28 10.1136/gutjnl-2019-319654 32066625
158. Vijay A Astbury S Le Roy C Spector TD Valdes AM The prebiotic effects of omega-3 fatty acid supplementation: a six-week randomised intervention trial Gut Microbes 2021 13 1 11 33382352
159. Jian C Luukkonen P Sädevirta S Yki-Järvinen H Salonen A Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults Clin Nutr 2021 40 207 16 10.1016/j.clnu.2020.05.008 32536582
160. So D Whelan K Rossi M Morrison M Holtmann G Kelly JT Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis Am J Clin Nutr 2018 107 965 83 10.1093/ajcn/nqy041 29757343
161. Myhrstad MCW, Tunsjø H, Charnock C, Telle-Hansen VH. Dietary fiber, gut microbiota, and metabolic regulation-current status in human randomized trials. Nutrients. 2020;12. 10.3390/nu12030859.
162. Houghton D Hardy T Stewart C Errington L Day CP Trenell MI Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes Diabetologia 2018 61 1700 11 10.1007/s00125-018-4632-0 29754286
163. Hartstra AV Schüppel V Imangaliyev S Schrantee A Prodan A Collard D Infusion of donor feces affects the gut-brain axis in humans with metabolic syndrome Mol Metab 2020 42 101076 10.1016/j.molmet.2020.101076 32916306
164. Hammeken LH Baunwall SMD Hvas CL Ehlers LH Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review Health Econ Rev 2021 11 3 10.1186/s13561-021-00301-7 33439367
165. Zhao HL Chen SZ Xu HM Zhou YL He J Huang HL Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta-analysis J Dig Dis 2020 21 534 48 10.1111/1751-2980.12933 33439534
166. de Groot P Nikolic T Pellegrini S Sordi V Imangaliyev S Rampanelli E Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial Gut 2021 70 92 105 10.1136/gutjnl-2020-322630 33106354
167. Pathak P Helsley RN Brown AL Buffa JA Choucair I Nemet I Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism Am J Physiol Heart Circ Physiol 2020 318 H1474 H1486 10.1152/ajpheart.00584.2019 32330092
168. Gupta N Buffa JA Roberts AB Sangwan N Skye SM Li L Targeted inhibition of gut microbial trimethylamine N-Oxide production reduces renal tubulointerstitial fibrosis and functional impairment in a murine model of chronic kidney disease Arterioscler Thromb Vasc Biol 2020 40 1239 55 10.1161/ATVBAHA.120.314139 32212854
169. Organ CL Li Z Sharp TE 3rd Polhemus DJ Gupta N Goodchild TT Nonlethal inhibition of gut microbial trimethylamine N-oxide production improves cardiac function and remodeling in a murine model of heart failure J Am Heart Assoc 2020 9 e016223 10.1161/JAHA.119.016223 32390485
170. Jiang H-Y Zhang X Yu Z-H Zhang Z Deng M Zhao J-H Altered gut microbiota profile in patients with generalized anxiety disorder J Psychiatr Res 2018 104 130 6 10.1016/j.jpsychires.2018.07.007 30029052
171. Chen Y-H Bai J Wu D Yu S-F Qiang X-L Bai H Association between fecal microbiota and generalized anxiety disorder: severity and early treatment response J Affect Disord 2019 259 56 66 10.1016/j.jad.2019.08.014 31437702
172. Chen Y-H Bai J Wu D Yu S-F Qiang X-L Bai H Corrigendum to ‘association between fecal microbiota and generalized anxiety disorder: severity and early treatment response’ [Journal of Affective Disorders 259(2019) 56–66] J Affect Disord 2020 260 489 10.1016/j.jad.2019.09.033 31539684
173. Hemmings SMJ Malan-Müller S van den Heuvel LL Demmitt BA Stanislawski MA Smith DG The microbiome in posttraumatic stress disorder and trauma-exposed controls: an exploratory study Psychosom Med 2017 79 936 46 10.1097/PSY.0000000000000512 28700459
174. Stevens BR Goel R Seungbum K Richards EM Holbert RC Pepine CJ Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression Gut 2018 67 1555 7 10.1136/gutjnl-2017-314759 28814485
175. Kelly JR Borre Y O’ Brien C Patterson E El Aidy S Deane J Transferring the blues: depression-associated gut microbiota induces neurobehavioural changes in the rat J Psychiatr Res 2016 82 109 18 10.1016/j.jpsychires.2016.07.019 27491067
176. Lin P Ding B Feng C Yin S Zhang T Qi X Prevotella and klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder J Affect Disord 2017 207 300 4 10.1016/j.jad.2016.09.051 27741466
177. Zhuang Z-Q Shen L-L Li W-W Fu X Zeng F Gui L Gut microbiota is altered in patients with Alzheimer’s disease J Alzheimers Dis 2018 63 1337 46 10.3233/JAD-180176 29758946

